Relmada Therapeutics, Inc. Common Stock
$4.22
-$0.22 (-4.95%)
$4.21Day Range$4.57
Key Statistics
Market Cap
$473.61M
Shares Outstanding
106.7M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Mar 3, 2014
Round Lot
100
Locale
US
Trading Data
Day Open
$4.45
Day High
$4.57
Day Low
$4.21
Volume
824.4K
VWAP
$4.27
Prev Close
$4.44
Transactions
--
Acc. Volume
--
About Relmada Therapeutics, Inc. Common Stock
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.
PHARMACEUTICAL PREPARATIONSSIC 283417 employees2222 PONCE DE LEON BLVD. 3RD FLOOR, CORAL GABLES, FL, 33134646 876 3459IPO Mar 3, 2014US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001553643
- Composite FIGI
- BBG003MKSL16
- Share Class FIGI
- BBG003MKSL25
- Ticker Root
- RLMD
- SIC Code
- 2834
About Relmada Therapeutics, Inc. Common Stock (RLMD) Stock
Relmada Therapeutics, Inc. Common Stock (RLMD) closed the 2026-09-16 session at $4.22, down 4.95% versus the previous close (-0.22). The stock opened at $4.45 and traded between $4.21 and $4.57 during that session. Session trading volume was 824K shares. The volume-weighted average price (VWAP) is $4.27.
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.
Relmada Therapeutics, Inc. Common Stock has a market capitalization of $473.6 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. RLMD is listed on the XNAS exchange. The company employs approximately 17 people. Relmada Therapeutics, Inc. Common Stock is headquartered in CORAL GABLES, FL. The recorded listing date is 2014-03-03.
On this page you can find market RLMD stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.